ACE-031 1mg – Myostatin Inhibitor

Description

ACE-031 1mg – ActRIIB-Fc Fusion Protein for Myostatin Inhibition Research

ACE-031 (also known as Ramatercept) is a recombinant fusion protein composed of the extracellular domain of the human activin receptor type IIB (ActRIIB) linked to the Fc portion of human immunoglobulin IgG1 . This research peptide functions as a potent soluble ligand trap, binding and neutralizing myostatin, activin A, and other negative regulators of skeletal muscle growth . By sequestering these ligands, ACE-031 effectively inhibits ActRIIB signaling pathways, promoting increased lean body mass and muscle fiber hypertrophy .

Key Research Applications

• Myostatin Inhibition Research – Studies the blockade of myostatin (GDF-8) and activin A signaling pathways, which are critical regulators of muscle growth inhibition .

• Muscle Wasting and Cachexia Models – Investigated in models of muscle atrophy, Duchenne muscular dystrophy (DMD), and chronic disease-related muscle loss .

• Muscle Hypertrophy Studies – Examines the mechanisms of ActRIIB ligand trap-induced skeletal muscle growth and fiber cross-sectional area increases .

• TGF-β Superfamily Signaling – Explores downstream SMAD signaling pathways and the cross-talk between myostatin, activin A, and other TGF-β family members .

• Skeletal Muscle Metabolism Research – Used in studies on muscle protein synthesis, satellite cell activation, and muscle regeneration .

Technical Specifications

• Molecular Weight: 2,956.5 Da 

• Molecular Formula: C₁₃₃H₂₂₇N₄₃O₃₃ 

• Purity: ≥98% (HPLC) 

• Form: Lyophilized powder 

• Dosage: 1mg per vial

• CAS Number: 1621169-52-5 

• Synonyms: Ramatercept, Myostatin inhibitory peptide 7, ActRIIB-Fc fusion protein 

• Storage: -20°C 

Reconstitution Guidelines

Reconstitute with sterile water or bacteriostatic water. Gently swirl (do not vortex) until fully dissolved. Once reconstituted, the product should be stored at -20°C in aliquots and used within 1 month to maintain stability and biological activity .

Research Background

In preclinical studies, ACE-031 has demonstrated significant increases in lean body mass and muscle fiber cross-sectional area. In a 14-week study on non-human primates (marmosets), ACE-031-treated subjects showed greater lean body mass and increased muscle force production compared to controls . In healthy volunteers, a single dose of ACE-031 resulted in up to 3.3% increase in total body lean mass and 5.1% increase in thigh muscle volume . These findings support the research value of ACE-031 in studying muscle mass regulation and growth pathway modulation.

Important Safety Notice

⚠️ FOR RESEARCH PURPOSES ONLY

This product is strictly intended for in-vitro research and laboratory use only. It is not approved for human consumption, therapeutic use, or clinical applications by any regulatory authority (e.g., FDA, EMA, etc.) . Due to safety concerns observed in clinical trials (including epistaxis and telangiectasias), the development of ACE-031 was terminated in Phase II . This product is for research use only.

ACE-031, Ramatercept, ActRIIB-Fc fusion protein, myostatin inhibitor, myostatin antagonist, soluble ActRIIB receptor, activin receptor type IIB, muscle growth research, muscle wasting, cachexia, Duchenne muscular dystrophy, TGF-β signaling, muscle hypertrophy, research peptide, lyophilized powder, 1mg, USA, research only.

ACE-031, Ramatercept, ActRIIB, Myostatin Inhibitor, Research Peptide, Muscle Growth, Muscle Wasting, Cachexia, TGF-β, Duchenne Muscular Dystrophy, DMD, Ligand Trap, USA

Follistatin 344 1mg – Myostatin Antagonist